Mandate

Vinge has advised XVIVO in conjunction with its directed share issue of SEK 440 million.

September 14, 2023 M&A

Vinge has advised XVIVO Perfusion AB in connection with its directed share issue at a subscription price of SEK 275 per share which corresponded to the closing price of XVIVO’s shares on Nasdaq Stockholm on the day of the issue.

XVIVO received SEK 440 million before issue costs. The subscription price was determined through an accelerated bookbuilding procedure arranged by Carnegie and DNB Markets. Investors in the directed share issue were both existing and new shareholders such as Bure Equity AB, the Fourth Swedish National Pension Fund, Swedbank Robur Fonder, Eccenovo, Handelsbanken Fonder, Tredje AP-fonden and a Tier-1 global international investor.

Vinge's team primarily consisted of Anders Strid and project manager Edin Agic.

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025